Table 1.

Continuous Glucose Monitoring AND Glycated Hemoglobin Target Attainment During Type 1 Diabetes Pregnancy

Type 1 diabetes pregnancy glucose targets	Percentage of women fulfilling glucose targets			P-value for change over time for both arms for RT-CGM, for control arm
	First trimester (N = 221)	24 Weeks (N = 197)	34 Weeks (N = 172)
	Both arms	Both arms	Both arms
	RT-CGM versus control	RT-CGM versus control	RT-CGM versus control
CGM
TIR 3.5–7.8 mmol/L (63–140 mg/dL) >70%	7.7	10.2	35.5	<0.001
	6.2 versus 9.3ns	10.5 versus 9.8ns	44.0 versus 27.3a	<0.001, <0.001
TAR >7.8 mmol/L (>140 mg/dL) <25%	14.5	14.2	37.2	<0.001
	15.9 versus 13ns	16.8 versus 11.8ns	46.4 versus 28.4a	<0.001, <0.01
TBR <3.5 mmol/L (<63 mg/dL) <4%	30.3	52.8	52.9	<0.001
	26.5 versus 34.3ns	53.7 versus 52ns	63.1 versus 43.2b	<0.001, <0.05
Laboratory
ADA trimester-specific HbA1c target	23.5	27.9	23.8	ns
	23.0 versus 24.1ns	30.5 versus 25.5ns	31.0 versus 17.0a	ns, ns
NICE HbA1c target <6.5% (48 mmol/mol)	23.5	59.4	54.1	<0.001
	23.0 versus 24.1ns	65.3 versus 53.9ns	63.1 versus 45.5a	<0.001, <0.001
HbA1c <6.0% (42 mmol/mol)	3.6	27.9	23.8	<0.001
	2.7 versus 4.6ns	30.5 versus 25.5ns	31.0 versus 17.0a	<0.001, <0.001

ADA indicates HbA_1c <6.5% (48 mmol/mol) as prepregnancy target and <6.0% (42 mmol/mol) in the second and third trimesters.

P value RT-CGM versus control: ^a<0.05; ^b<0.01.

ADA, American Diabetes Association; CGM, continuous glucose monitoring; HbA_1c, glycated hemoglobin; NICE, National Institute for Health and Care Excellence; NS, nonsignificant; RT-CGM, real-time CGM; TAR, Time-above-range; TBR, Time-below-range; TIR, Time-in-range.